PepGen Inc. (PEPG)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about PepGen Inc. (PEPG)

Company Performance

Current Price

as of Oct 18, 2024

$8.94

P/E Ratio

N/A

Market Cap

$291.35M

Description

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Metrics

Overview

HQBoston, MA
SectorHealth Technology
IndustryBiotechnology
TickerPEPG
Price$8.94+0.79%

Trading Information

Market Cap$291.35M
Float79.06%
Average Daily Volume (1m)87,454
Average Daily Volume (3m)149,715
EPS-$3.30

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$28.33M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$30.06M

EV$376.31M
EV/RevenueN/A
P/EN/A
P/SN/A
P/B1.88

Documents

Earnings Calls

Earnings Report 2023Q4

Earnings Report (2023-03-25)

Factset

Factset Business Description

Factset Street Account

PepGen reports Q3 EPS ($0.98) vs FactSet ($0.88) [5 est, ($1.06)-(0.71)] ($5.00, 0.00) (2023-11-08T13:02:31Z)

PepGen first patient dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) ($6.63, 0.00) (2023-12-18T13:09:51Z)

PepGen announces FDA has lifted clinical hold on IND for FREEDOM-DM1 phase 1 study of PGN-EDODM1 ($5.26, 0.00) (2023-10-12T11:07:14Z)